ACN Newswire

Clinical validation results confirm PromarkerD can predict diabetic kidney disease better than any current measure

SAN DIEGO, CA, June 12, 2017 – (ACN Newswire) – Proteomics International Laboratories Ltd (‘PILL’, ASX: PIQ), a global leader in applying proteomics to MedTech, has announced results from the clinical validation study showing that its PromarkerD blood test can predict the onset of diabetic kidney disease (DKD) better than any current measure.

Link to article